ArticleBMC surgery2025
Analysis of the efficacy of drug-coated balloons in the treatment of venous stenosis in hemodialysis access.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety and efficacy of drug-coated balloon (DCB) and conventional balloon (CB) in the treatment of venous stenosis in hemodialysis access.
methodThe clinical data of 403 hemodialysis patients with arteriovenous fistula stenosis who were admitted to our hospital from November 1, 2020 to January 1, 2024 were retrospectively analyzed and divided into DCB group (n = 163) and CB group (n = 240). The Kaplan-Meier curve was used to evaluate the target lesion primary patency (TLPP) of the two groups. The primary endpoint was the primary patency rate of target lesions 12 months after surgery, and the secondary endpoints were the primary patency rates of target lesions 6 months, 18 months, and 24 months. Cox proportional hazard models were applied to explore the association between DCB and the risk of hemodialysis access dysfunction.
resultsThe primary patency rate of target lesions in DCB group was higher at 6 months, 12 months, 18 months and 24 months, and the difference was statistically significant at 6 months (85.0% VS 69.3%, P = 0.0109) and 12 months (64.6% VS 38.0%, 0.0300).There was no significant difference at 18 months (36.9% VS 14.9%, P = 0.1475) and 24 months (23.1% VS 7.5%, P = 0.5091). The median survival time of DCB group was 449 days, and that of CB group was 270 days. The patency time of DCB group was significantly higher than that of CB group (P < 0.0001). After full covariate adjustment, the analysis revealed that patients in DCB group (HR: 0.34, 95% CI: 0.16, 0.70) had a significantly lower risk of hemodialysis access dysfunction compared to those in CB group.
conclusionThe results show that compared with CB, DCB can obviously improve the primary patency rate of target lesions with vascular access stenosis in hemodialysis and reduce the re-intervention of target lesions, which is an effective and safe treatment for hemodialysis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.